Background: Peritoneal dialysis (PD) patients with impaired hand–eye function require helper assistance. Our centre developed a connection device that assists patients with impaired hand–eye function to perform PD exchange themselves, but the clinical outcomes in these patients have not been investigated. Methods: We retrospectively reviewed patients who had device-assisted continuous ambulatory peritoneal dialysis (CAPD) during 2007–2016 and compared their clinical outcomes with age- and sex-matched patients receiving helper-assisted CAPD. Results: One hundred seventy-two patients (86 each in the device- and helper-assisted CAPD groups) were followed for 29.9 (19.4–43.3) months. The device- and helper-assisted groups had comparable peritonitis rates (0.489 and 0.504 episode per patient-year, respectively, p = 0.814), with no difference in the distribution of causative organisms and the organism-specific peritonitis rates. The device-assisted group showed similar peritonitis-free survival compared with the helper-assisted group (2.58 (1.85–3.31) vs. 1.78 (0.68–2.88) years, p = 0.363) and time-to-PD discontinuation (6.27 (3.65–8.90) vs. 4.35 (3.48–5.22) years, p = 0.677). The median patient survival was similar between the two groups (3.89 (2.22–5.55) vs. 3.81 (3.27–4.36) years in the device- and helper-assisted groups, respectively, p = 0.505). Conclusion: Device-assisted CAPD confers comparable outcomes as helper-assisted CAPD and is a viable option in PD patients with impaired hand–eye function.
Background: Eosinophilic peritonitis is a well-known complication at the initiation of peritoneal dialysis. It is often due to an allergic reaction to peritoneal dialysis solution or sometimes to the peritoneal dialysis catheter itself. Most cases are self-limiting with expected spontaneous resolution within a few weeks. Treatment is necessary for severe or persistent cases. However, the optimal treatment has not yet been defined. There have been only a few case reports on the use of anti-histamines and/or steroids for the treatment of eosinophilic peritonitis. We reported a case of severe eosinophilic peritonitis successfully treated by switching the brand of peritoneal dialysis fluid (same glucose concentration). To the best of our knowledge, this is the first reported case employing such a treatment strategy. Case presentation: An eighty-two-year-old man with end-stage renal failure was started on continuous ambulatory peritoneal dialysis with Dianeal® (Baxter) peritoneal dialysis solution. He developed eosinophilic peritonitis 19 days after initiation of peritoneal dialysis. Infectious causes were ruled out by bacterial, fungal and tuberculosis smears and cultures. In view of the persistent and severe symptoms, we intervened by switching from Dianeal® (Baxter) peritoneal dialysis solution to Stay-Safe Balance® (Fresenius) solution with the same glucose concentration. His eosinophilic peritonitis resolved 5 days after switching the peritoneal dialysis solution. Conclusion: In severe or persistent cases of eosinophilic peritonitis requiring treatment, other than the use of steroids and anti-histamines, switching to a different brand of peritoneal dialysis solution can be considered.
2 September 2025 in Peritoneal Dialysis International: Journal of the International Society for Peritoneal Dialysis
Mycobacterium tuberculosis (MTB)-related peritonitis is a rare but serious complication in patients receiving maintenance peritoneal dialysis (PD). Early diagnosis is difficult due to the low sensitivity and delayed results of conventional microscopy and culture methods. MTB polymerase chain reaction (PCR) testing in PD effluent is recommended as a diagnostic adjunct, but real-world data remain limited. We conducted a 20-year single-centre retrospective study in a tuberculosis-endemic region to evaluate the diagnostic accuracy and clinical utility of MTB-PCR in PD effluent. Among 372 tests, MTB-PCR demonstrated sensitivity 50%, specificity 100%, negative-predictive value 94.6% and positive-predictive value 100%, using diagnoses based on a composite of clinical and laboratory criteria as the reference standard. Sensitivity showed a numerical trend of improvement from 33.3% with earlier assays to 50–85.7% with newer assays. Of 72 patients with culture-confirmed MTB-PD peritonitis, 13 (18.1%) were diagnosed via MTB-PCR. Compared to those diagnosed by non-PCR methods, MTB-PCR-diagnosed patients had shorter time to anti-tuberculosis treatment initiation (median 8 vs. 22 days, p ≤ 0.001) and shorter hospital stay from presentation to treatment (median 8 vs. 17 days, p = 0.008). They also had a numerically lower rate of PD catheter removal prior to treatment initiation [0/13 (0%) vs. 9/53 patients (17.0%), p = 0.186]. Rates of permanent transfer to haemodialysis and all-cause mortality at 1 year were similar among the two groups. These findings suggest a role for early MTB-PCR testing in suspected MTB-PD peritonitis. Further studies are needed to confirm the findings and optimize diagnostic strategies.